CORRECTING and REPLACING -- Unum Therapeutics Announces 2019 Goals and Expected Milestones
January 04 2019 - 6:15PM
In a release issued yesterday under the same headline
by Unum Therapeutics Inc. (NASDAQ: UMRX), please
note the anticipated 2019 milestone for BOXR1030 has been changed
from initiating clinical development to initiating preclinical
development in the last paragraph. The corrected release
follows:
Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage
biopharmaceutical company focused on the development of novel
cellular immunotherapies, today announced its anticipated
milestones for 2019.
“Unum made substantial progress in 2018 as we reported early
data from our programs in non-Hodgkin lymphoma and multiple
myeloma, while simultaneously expanding applications of our ACTR
platform into solid tumors and introducing a second novel
technology platform, BOXR, designed to improve the functionality of
engineered T cells,” said Chuck Wilson, CEO of Unum. “We expect
2019 also to be a year of significant momentum, with data expected
from all four of our ongoing clinical programs, including readouts
from the ATTCK-20-03 and ATTCK-17-01 trials, as well as an initial
data readout from our first study in solid tumors. Additionally, we
continue to innovate in the field of cell therapy and have recently
nominated our first development candidate from our BOXR technology
platform to advance toward clinical development.”
Anticipated 2019 Milestones
ACTR707 + rituximab in r/r NHL
- Complete the dose escalation phase of ATTCK-20-03, the ongoing,
multicenter Phase 1 study testing ACTR707 in combination with
rituximab to treat patients with relapsed/refractory B cell
non-Hodgkin lymphoma. Advance into cohort expansion to confirm the
preliminary recommended Phase 2 dose.
- Report results from the dose escalation phase and preliminary
data from the cohort expansion phase of the ATTCK-20-03 study.
ACTR087 + SEA-BCMA in r/r multiple myeloma
- Progress dose escalation of ACTR087 and SEA-BCMA in
ATTCK-17-01, a Phase 1, multi-center, open-label trial designed to
test the safety, tolerability and anti-myeloma activity of the
combination in patients with r/r multiple myeloma.
- Report clinical data from multiple cohorts of the dose
escalation phase.
ACTR707 + trastuzumab in HER2+ advanced cancers
- Enroll and dose patients in Unum’s first ACTR T cell study in
solid tumors, ATTCK-34-01, a multicenter, single-arm, open-label
dose escalation study evaluating ACTR T cells in combination with
trastuzumab in patients with HER2+ advanced cancers.
- Report initial clinical data from ongoing dose escalation.
ACTR087 + rituximab in r/r NHL
- Complete enrollment in ATTCK-20-2, a Phase I clinical trial
evaluating safety and anti-lymphoma activity of ACTR087 in
combination with rituximab in patients with relapsed or refractory
B cell NHL, and report data from the trial.
BOXR Platform
- Continued progress with new Bolt-On Chimeric Receptor
technology platform (“BOXR”) that improves T cell functionality by
countering immunosuppression in solid tumor cancers. Initiate
preclinical development of BOXR1030, which has been nominated as
the first product candidate from this platform.
About Unum Therapeutics
Unum Therapeutics is a clinical-stage biopharmaceutical company
focused on the development and commercialization of novel
immunotherapy products designed to harness the power of a patient’s
immune system to cure cancer. Unum’s novel proprietary technologies
include Antibody-Coupled T cell Receptor (ACTR), a universal,
engineered cell therapy intended to be used in combination with a
wide range of tumor-specific antibodies to target different tumor
types, and Bolt-On Chimeric Receptor (BOXR), an approach for
improving T cell functionality to enable solid tumor cancer
applications. Unum has four product candidates currently in Phase I
clinical testing, including: ACTR707 used in combination with
rituximab, an anti-CD20 antibody, in adult patients with relapsed
or refractory non-Hodgkin lymphoma (r/r NHL); ACTR087 used in
combination with the novel antibody SEA-BCMA in adult patients with
relapsed or refractory multiple myeloma; and ACTR707 used in
combination with trastuzumab, an anti-human epidermal growth factor
receptor 2 (HER2) antibody, in adult patients with HER2+ advanced
cancer.
The Company is headquartered in Cambridge, MA.
Forward looking Statements
This press release contains forward-looking statements.
Statements in this press release about our future expectations,
plans and prospects, including projections regarding future
revenues and financial performance, the anticipated timing of our
clinical trials and regulatory filings, our long-term growth and
our ability to achieve our strategy, the design of our clinical
trials, the development of our product candidates, including the
three lead ACTR product candidates, the results of our clinical
trials, as well as other statements containing the words
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "might," "plan," "potential," "predict,"
"project," "should," "target," "will," or "would" and similar
expressions, constitute forward-looking statements within the
meaning of the safe harbor provisions of The Private Securities
Litigation Reform Act of 1995. We may not actually achieve the
forecasts disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking statements.
Actual results could differ materially from the projections
disclosed in the forward-looking statements we make as a result of
a variety of risks and uncertainties, including risks related to
the accuracy of our estimates regarding expenses, future revenues,
capital requirements, and the need for additional financing, the
success, cost and timing of our product development activities and
clinical trials, our ability to obtain and maintain regulatory
approval for our product candidates, and the other risks and
uncertainties described in the "Risk Factors" sections of our
public filings with the Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent our views as of the date hereof. We anticipate
that subsequent events and developments may cause our views to
change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should
not be relied upon as representing our views as of any date
subsequent to the date hereof.
Investor Contact:Stephanie Ascher,
212-362-1200stephanie@sternir.com
Media Contact: Paul Kidwell,
617-680-1088paul.kidwell@unumrx.com
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024